All News

    First Patient Dosed in Trial of [212Pb]VMT01 for Metastatic Melanoma

    March 30th 2025, 6:00pm

    Article

    The first patient has been dosed with [212Pb]VMT01 in a phase 1/2a trial evaluating the safety of the agent in patients with melanoma.

    What Patients With Kidney Cancer Need to Know From ASCO GU

    March 30th 2025, 2:00pm

    Article

    There were a number of notable developments for patients with kidney cancer at the symposium, Dr. Emre Yekedüz explained.

    Research Shines Light on Disparities Across Breast Cancer Care

    March 29th 2025, 2:00pm

    Video

    Dr. Regina Hampton discusses key factors contributing to this disparity, and how healthcare systems can address these challenges.

    FDA Approves Imfinzi Therapy in Muscle Invasive Bladder Cancer

    March 28th 2025, 9:11pm

    Article

    The FDA approved neoadjuvant Imfinzi, gemcitabine and cisplatin, followed by adjuvant Imfinzi after radical cystectomy in muscle invasive bladder cancer.

    Life Goes On, Even With Breast Cancer

    March 28th 2025, 8:00pm

    Article

    I reflect on how cancer has brought out resilience and support in others, even as I struggled with my own battle, and wish others strength in their journeys.

    Why Physical Therapy Should Begin at the Time of a Cancer Diagnosis

    March 28th 2025, 7:11pm

    Video

    CURE spoke with Leslie Waltke about the importance of physical therapy during a cancer journey.

    FDA Expands Pluvicto Indication in Prostate Cancer Subset

    March 28th 2025, 5:13pm

    Article

    FDA expands Pluvicto indication to adults with PSMA+ metastatic castration-resistant prostate cancer previously treated with androgen receptor inhibitors.

    SON-1010 Generates Safe Results in Advanced Sarcoma

    March 28th 2025, 4:00pm

    Article

    A phase 1 trial has reported positive safety findings of SON-1010 among patients with advanced leiomyosarcoma (LMS) or liposarcoma (LPS).

    Solnerstotug Demonstrates Early Efficacy in PD-L1 Resistant Tumors

    March 28th 2025, 3:00pm

    Article

    Favorable initial results from a phase 1/2 trial of solnerstotug in PD-L1–resistant tumors showed a 14% response rate and 62% disease control rate.

    Childhood Cancer Survivors May Experience Sooner Aging-Related Disease

    March 28th 2025, 1:00pm

    Article

    Researchers have found childhood cancer survivors are at risk of experiencing onset of aging-related disease 17.7 years sooner than the general population.